JT002

JT002 is an orally active and selective NLRP3 inflammasome assembly inhibitor. JT002 reduces NLRP3-dependent proinflammatory cytokine (such as IL-1β, IL-1α, IL-18) production and pyroptosis. JT002 blocks NLRP3 inflammasome complex formation. JT002 reduces airway hyperresponsiveness and airway neutrophilia in mice. JT002 can be used for the study of a variety of inflammatory diseases, such as Muckle-Wells syndrome (MWS) [1].

Product Specifications

CAS Number

[2238820-43-2]

UNSPSC

12352005

Target

NOD-like Receptor (NLR) ; Pyroptosis

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/jt002.html

Purity

99.54

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NS(=O)(C1=C(OC[C@@H](OC)C2)N2N=C1)=O)NC3=C(CCC4)C4=CC5=C3CCC5

Molecular Formula

C20H24N4O5S

Molecular Weight

432.49

References & Citations

[1]Ambrus-Aikelin G, et al. JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders. Sci Rep. 2023 Aug 19;13 (1) :13524.